| API Access | |

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from Kringle Pharma,Inc. was processed by Pulse News Wire on April 1, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Kringle Pharma announces large-scale exercise of 16th warrant issue

TOKYO, Apr 01 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) announced the large-scale exercise of its 16th warrant issue on April 01, 2026. The warrants, allocated to EVO FUND and issued on August

View all Kringle Pharma,Inc. disclosures →

Kringle Pharma,Inc. [4884.T]

TOKYO, Apr 01 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) announced the large-scale exercise of its 16th warrant issue on April 01, 2026.

The warrants, allocated to EVO FUND and issued on August 01, 2025, saw the exercise of 2,083,110 warrants out of a total issuance of 2,083,110. As of March 31, 2026, there were 1,041,555 unexercised warrants remaining.

On April 01, 2026, the delivery of shares amounted to 2,083,110, with an exercise price of ¥416 per warrant. At the end of March 31, 2026, the total number of outstanding shares was 7,395,200, including 183 treasury shares.

Original Disclosure (PDF)

🟡 Confidence: Standard AI-translated content.